COR2ED Medical Education
@cor2ed.com
COR2ED develops high-quality Independent Medical Education programmes for HCPs globally.
Visit our website: https://cor2ed.com/
Read the Community Guidelines: https://t.co/KZbQi7TR4U
#MedEd #IME #MedicalEducation
Visit our website: https://cor2ed.com/
Read the Community Guidelines: https://t.co/KZbQi7TR4U
#MedEd #IME #MedicalEducation
▶️ Neurological symptoms of hypophosphatasia: unifyrare.com/en/closing-t...
Programme initiated and funded by Alexion, AstraZeneca Rare Disease. Brought to you by COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0101 | Dec 2025
Programme initiated and funded by Alexion, AstraZeneca Rare Disease. Brought to you by COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0101 | Dec 2025
December 19, 2025 at 10:03 AM
▶️ Neurological symptoms of hypophosphatasia: unifyrare.com/en/closing-t...
Programme initiated and funded by Alexion, AstraZeneca Rare Disease. Brought to you by COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0101 | Dec 2025
Programme initiated and funded by Alexion, AstraZeneca Rare Disease. Brought to you by COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0101 | Dec 2025
We're proud to share that more than 50k HCPs now follow us online!🎉
>25k YouTube subscribers
>25k social media followers
Follow us for engaging #medicaleducation developed by renowned medical experts & endorsed by Medical Societies & Patient Advocacy Groups
www.youtube.com/@cor2edthehe...
#MedSky
>25k YouTube subscribers
>25k social media followers
Follow us for engaging #medicaleducation developed by renowned medical experts & endorsed by Medical Societies & Patient Advocacy Groups
www.youtube.com/@cor2edthehe...
#MedSky
December 16, 2025 at 11:42 AM
We're proud to share that more than 50k HCPs now follow us online!🎉
>25k YouTube subscribers
>25k social media followers
Follow us for engaging #medicaleducation developed by renowned medical experts & endorsed by Medical Societies & Patient Advocacy Groups
www.youtube.com/@cor2edthehe...
#MedSky
>25k YouTube subscribers
>25k social media followers
Follow us for engaging #medicaleducation developed by renowned medical experts & endorsed by Medical Societies & Patient Advocacy Groups
www.youtube.com/@cor2edthehe...
#MedSky
ESMO 2025: Gastric and gastroesophageal cancer insights for clinical practice
On-demand video and slides from an Experts Knowledge Share event
▶️ cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Amgen
#MedEd #MedicalEducation
On-demand video and slides from an Experts Knowledge Share event
▶️ cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Amgen
#MedEd #MedicalEducation
December 11, 2025 at 12:09 PM
ESMO 2025: Gastric and gastroesophageal cancer insights for clinical practice
On-demand video and slides from an Experts Knowledge Share event
▶️ cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Amgen
#MedEd #MedicalEducation
On-demand video and slides from an Experts Knowledge Share event
▶️ cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Amgen
#MedEd #MedicalEducation
#Hypophosphatasia across 3 generations – can you help make their dream a reality?
▶️ unifyrare.com/en/closing-t...
Programme initiated and funded by Alexion, AstraZeneca Rare Disease. Brought to you by COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0099 | Dec 2025
▶️ unifyrare.com/en/closing-t...
Programme initiated and funded by Alexion, AstraZeneca Rare Disease. Brought to you by COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0099 | Dec 2025
December 8, 2025 at 11:59 AM
#Hypophosphatasia across 3 generations – can you help make their dream a reality?
▶️ unifyrare.com/en/closing-t...
Programme initiated and funded by Alexion, AstraZeneca Rare Disease. Brought to you by COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0099 | Dec 2025
▶️ unifyrare.com/en/closing-t...
Programme initiated and funded by Alexion, AstraZeneca Rare Disease. Brought to you by COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0099 | Dec 2025
Closing the Gap in HPP Care 2025
webapp.spotme.com/login/alexio...
📅 2 & 4 December | Live sessions
Initiated and funded by Alexion, AstraZeneca Rare Disease and brought to you in collaboration with COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0096 | Nov 2025
webapp.spotme.com/login/alexio...
📅 2 & 4 December | Live sessions
Initiated and funded by Alexion, AstraZeneca Rare Disease and brought to you in collaboration with COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0096 | Nov 2025
November 17, 2025 at 9:03 AM
Closing the Gap in HPP Care 2025
webapp.spotme.com/login/alexio...
📅 2 & 4 December | Live sessions
Initiated and funded by Alexion, AstraZeneca Rare Disease and brought to you in collaboration with COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0096 | Nov 2025
webapp.spotme.com/login/alexio...
📅 2 & 4 December | Live sessions
Initiated and funded by Alexion, AstraZeneca Rare Disease and brought to you in collaboration with COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0096 | Nov 2025
Today is #WorldHPPDay
#Hypophosphatasia (HPP) is a #RareDisease that can impact working, connecting, and living independently
In the video (GL/UNB-H/0096), Suzanne & Amy share their HPP stories 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0095
#Hypophosphatasia (HPP) is a #RareDisease that can impact working, connecting, and living independently
In the video (GL/UNB-H/0096), Suzanne & Amy share their HPP stories 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0095
October 30, 2025 at 9:19 AM
Today is #WorldHPPDay
#Hypophosphatasia (HPP) is a #RareDisease that can impact working, connecting, and living independently
In the video (GL/UNB-H/0096), Suzanne & Amy share their HPP stories 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0095
#Hypophosphatasia (HPP) is a #RareDisease that can impact working, connecting, and living independently
In the video (GL/UNB-H/0096), Suzanne & Amy share their HPP stories 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0095
Rethinking HPP (hypophosphatasia)
➡️ HPP is an inherited disorder that can impact a patient’s ability to work, connect, and live independently
Watch the video (GL/UNB-H/0087) for key facts 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0091
#RareDiseases
➡️ HPP is an inherited disorder that can impact a patient’s ability to work, connect, and live independently
Watch the video (GL/UNB-H/0087) for key facts 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0091
#RareDiseases
October 23, 2025 at 10:40 AM
Rethinking HPP (hypophosphatasia)
➡️ HPP is an inherited disorder that can impact a patient’s ability to work, connect, and live independently
Watch the video (GL/UNB-H/0087) for key facts 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0091
#RareDiseases
➡️ HPP is an inherited disorder that can impact a patient’s ability to work, connect, and live independently
Watch the video (GL/UNB-H/0087) for key facts 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0091
#RareDiseases
Reposted by COR2ED Medical Education
Colleagues at #ESMO25 , Join our Collaborators at COR2ED and Dr. Lizzy Smyth straight from Berlin 👉 cor2ed.com/esmo-2025/up...
Dr Smyth will review key studies including MATTERHORN, LEAP-014, and SKYSCRAPER-07 — and discuss whether these results could change clinical practice.
Dr Smyth will review key studies including MATTERHORN, LEAP-014, and SKYSCRAPER-07 — and discuss whether these results could change clinical practice.
October 19, 2025 at 9:00 AM
Colleagues at #ESMO25 , Join our Collaborators at COR2ED and Dr. Lizzy Smyth straight from Berlin 👉 cor2ed.com/esmo-2025/up...
Dr Smyth will review key studies including MATTERHORN, LEAP-014, and SKYSCRAPER-07 — and discuss whether these results could change clinical practice.
Dr Smyth will review key studies including MATTERHORN, LEAP-014, and SKYSCRAPER-07 — and discuss whether these results could change clinical practice.
Reposted by COR2ED Medical Education
Colleagues at #ESMO25
Dr Herbert Loong shares his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Go to the COR2ED website to watch his video update and download the accompanying slides
cor2ed.com/esmo-2025/on...
Dr Herbert Loong shares his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Go to the COR2ED website to watch his video update and download the accompanying slides
cor2ed.com/esmo-2025/on...
October 20, 2025 at 9:30 AM
Colleagues at #ESMO25
Dr Herbert Loong shares his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Go to the COR2ED website to watch his video update and download the accompanying slides
cor2ed.com/esmo-2025/on...
Dr Herbert Loong shares his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Go to the COR2ED website to watch his video update and download the accompanying slides
cor2ed.com/esmo-2025/on...
Reposted by COR2ED Medical Education
Prof. Viktor Grünwald shares his renal cell carcinoma highlights from ESMO 2025 as he reviews the latest data from the LenCabo, KEYMAKER-U03 and CLEAR studies. He also discusses staging of disease with the radiolabelled peptide ([68Ga]Ga-DPI-4452).
cor2ed.com/esmo-2025/re...
cor2ed.com/esmo-2025/re...
October 21, 2025 at 8:30 AM
Prof. Viktor Grünwald shares his renal cell carcinoma highlights from ESMO 2025 as he reviews the latest data from the LenCabo, KEYMAKER-U03 and CLEAR studies. He also discusses staging of disease with the radiolabelled peptide ([68Ga]Ga-DPI-4452).
cor2ed.com/esmo-2025/re...
cor2ed.com/esmo-2025/re...
Reposted by COR2ED Medical Education
Dear Colleagues, Our Collaborators at COR2ED Invite you to watch Highlights from #ESMO25
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
October 23, 2025 at 10:02 AM
Dear Colleagues, Our Collaborators at COR2ED Invite you to watch Highlights from #ESMO25
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
How can new clinical trials in radioligand therapy impact clinical practice in #NET treatment strategies?
Find out in this new #MedEd video from medical experts
cor2ed.com/net-connect/...
Supported by an Independent Educational Grant from ITM
@nanets.bsky.social #MedSky #medicaleducation 📷
Find out in this new #MedEd video from medical experts
cor2ed.com/net-connect/...
Supported by an Independent Educational Grant from ITM
@nanets.bsky.social #MedSky #medicaleducation 📷
October 6, 2025 at 3:00 PM
How can new clinical trials in radioligand therapy impact clinical practice in #NET treatment strategies?
Find out in this new #MedEd video from medical experts
cor2ed.com/net-connect/...
Supported by an Independent Educational Grant from ITM
@nanets.bsky.social #MedSky #medicaleducation 📷
Find out in this new #MedEd video from medical experts
cor2ed.com/net-connect/...
Supported by an Independent Educational Grant from ITM
@nanets.bsky.social #MedSky #medicaleducation 📷
📢 New #dermatology micro learning!
Improving acne vulgaris with multimodal treatment strategies
>> cor2ed.com/dermatology-...
📺 4-min video, downloadable flashcard & slides, and accredited assessment
Supported by an Independent Educational Grant from Glenmark Pharmaceuticals
#MedSky
Improving acne vulgaris with multimodal treatment strategies
>> cor2ed.com/dermatology-...
📺 4-min video, downloadable flashcard & slides, and accredited assessment
Supported by an Independent Educational Grant from Glenmark Pharmaceuticals
#MedSky
Improving acne vulgaris with multimodal treatment strategies | COR2ED
In this micro learning module, developed by experts Prof. Alison Layton and Prof. Dr Falk Ochsendorf, you will explore multimodal treatment strategies for
cor2ed.com
August 11, 2025 at 1:29 PM
📢 New #dermatology micro learning!
Improving acne vulgaris with multimodal treatment strategies
>> cor2ed.com/dermatology-...
📺 4-min video, downloadable flashcard & slides, and accredited assessment
Supported by an Independent Educational Grant from Glenmark Pharmaceuticals
#MedSky
Improving acne vulgaris with multimodal treatment strategies
>> cor2ed.com/dermatology-...
📺 4-min video, downloadable flashcard & slides, and accredited assessment
Supported by an Independent Educational Grant from Glenmark Pharmaceuticals
#MedSky
2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes.
Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:
Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:
August 11, 2025 at 1:20 PM
🔎 Expert insights on recent #BreastCancer data
Dr Paolo Tarantino discusses data from SERENA-6, ASCENT-04/KEYNOTE-D19 & DESTINY-Breast09 studies presented at #ASCO25
Watch his video & see more ASCO updates
▶️ cor2ed.com/n-connect/pr...
Supported by COR2ED #MedEd #MedSky @ptarantinomd.bsky.social
Dr Paolo Tarantino discusses data from SERENA-6, ASCENT-04/KEYNOTE-D19 & DESTINY-Breast09 studies presented at #ASCO25
Watch his video & see more ASCO updates
▶️ cor2ed.com/n-connect/pr...
Supported by COR2ED #MedEd #MedSky @ptarantinomd.bsky.social
July 8, 2025 at 10:25 AM
🔎 Expert insights on recent #BreastCancer data
Dr Paolo Tarantino discusses data from SERENA-6, ASCENT-04/KEYNOTE-D19 & DESTINY-Breast09 studies presented at #ASCO25
Watch his video & see more ASCO updates
▶️ cor2ed.com/n-connect/pr...
Supported by COR2ED #MedEd #MedSky @ptarantinomd.bsky.social
Dr Paolo Tarantino discusses data from SERENA-6, ASCENT-04/KEYNOTE-D19 & DESTINY-Breast09 studies presented at #ASCO25
Watch his video & see more ASCO updates
▶️ cor2ed.com/n-connect/pr...
Supported by COR2ED #MedEd #MedSky @ptarantinomd.bsky.social
🚨 Best practices in managing early relapsed/refractory multiple myeloma
3-part video series with expert insights & downloadable slide sets
⬇️
cor2ed.com/lymphoma-mye...
Supported by an Independent Educational Grant from Menarini Stemline Oncology
#MedSky #MedEd #RRMM
3-part video series with expert insights & downloadable slide sets
⬇️
cor2ed.com/lymphoma-mye...
Supported by an Independent Educational Grant from Menarini Stemline Oncology
#MedSky #MedEd #RRMM
Early relapsed/refractory multiple myeloma (RRMM): best practices in management | COR2ED
cor2ed.com
July 3, 2025 at 10:16 AM
🚨 Best practices in managing early relapsed/refractory multiple myeloma
3-part video series with expert insights & downloadable slide sets
⬇️
cor2ed.com/lymphoma-mye...
Supported by an Independent Educational Grant from Menarini Stemline Oncology
#MedSky #MedEd #RRMM
3-part video series with expert insights & downloadable slide sets
⬇️
cor2ed.com/lymphoma-mye...
Supported by an Independent Educational Grant from Menarini Stemline Oncology
#MedSky #MedEd #RRMM
➡️Tx strategies for pts w/ advanced #HCC who are ineligible for #immunotherapy or with progression on #IO
👉 cor2ed.com/hcc-connect/...
Endorsed by @digestivecancerseu.bsky.social @bluefaeryliver.bsky.social @aasldnews.bsky.social @europeliver.bsky.social
Supported by an IME Grant from Bayer #meded
👉 cor2ed.com/hcc-connect/...
Endorsed by @digestivecancerseu.bsky.social @bluefaeryliver.bsky.social @aasldnews.bsky.social @europeliver.bsky.social
Supported by an IME Grant from Bayer #meded
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO) | COR2ED
In this micro learning, developed by experts Assoc. Prof. Lorenza Rimassa and Dr Amit Singal, you will learn about treatment strategies for patients who
cor2ed.com
July 2, 2025 at 6:51 PM
➡️Tx strategies for pts w/ advanced #HCC who are ineligible for #immunotherapy or with progression on #IO
👉 cor2ed.com/hcc-connect/...
Endorsed by @digestivecancerseu.bsky.social @bluefaeryliver.bsky.social @aasldnews.bsky.social @europeliver.bsky.social
Supported by an IME Grant from Bayer #meded
👉 cor2ed.com/hcc-connect/...
Endorsed by @digestivecancerseu.bsky.social @bluefaeryliver.bsky.social @aasldnews.bsky.social @europeliver.bsky.social
Supported by an IME Grant from Bayer #meded
Congratulations to the newly elected ESMO Directors & Nomination Committee members!
A special mention to:
👏 GI CONNECT's Dr @lizzysmyth.bsky.social
👏 PRECISION ONCOLOGY CONNECT's Prof. Ulrik Lassen
👏 Prof. Rachel Riechelmann, who has collaborated with NET CONNECT
#MedicalEducation #ESMO #MedSky
A special mention to:
👏 GI CONNECT's Dr @lizzysmyth.bsky.social
👏 PRECISION ONCOLOGY CONNECT's Prof. Ulrik Lassen
👏 Prof. Rachel Riechelmann, who has collaborated with NET CONNECT
#MedicalEducation #ESMO #MedSky
ESMO announces the 2025 election results for the Director positions and the Nomination Committee.
Thank you to all #ESMOMembers who voted and contributed to shaping the Society’s future direction.
📢 Curious to see who was elected?
🔗 Read the full announcement: buff.ly/F1beK90
Thank you to all #ESMOMembers who voted and contributed to shaping the Society’s future direction.
📢 Curious to see who was elected?
🔗 Read the full announcement: buff.ly/F1beK90
June 18, 2025 at 7:57 AM
Congratulations to the newly elected ESMO Directors & Nomination Committee members!
A special mention to:
👏 GI CONNECT's Dr @lizzysmyth.bsky.social
👏 PRECISION ONCOLOGY CONNECT's Prof. Ulrik Lassen
👏 Prof. Rachel Riechelmann, who has collaborated with NET CONNECT
#MedicalEducation #ESMO #MedSky
A special mention to:
👏 GI CONNECT's Dr @lizzysmyth.bsky.social
👏 PRECISION ONCOLOGY CONNECT's Prof. Ulrik Lassen
👏 Prof. Rachel Riechelmann, who has collaborated with NET CONNECT
#MedicalEducation #ESMO #MedSky
📹 Watch the video > cor2ed.com/n-connect/pr...
Video: The evolution of our understanding that led us to rethink #hypophosphatasia (HPP) 💡
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #MedSky #EULAR2025
Video: The evolution of our understanding that led us to rethink #hypophosphatasia (HPP) 💡
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #MedSky #EULAR2025
Rethinking hypophosphatasia (HPP) diagnosis and disease burden | COR2ED
cor2ed.com
June 12, 2025 at 4:21 PM
📹 Watch the video > cor2ed.com/n-connect/pr...
Video: The evolution of our understanding that led us to rethink #hypophosphatasia (HPP) 💡
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #MedSky #EULAR2025
Video: The evolution of our understanding that led us to rethink #hypophosphatasia (HPP) 💡
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #MedSky #EULAR2025
📣Update from #ASCO25
Expert insights on the latest data: cor2ed.com/n-connect/pr...
#NSCLC #ProstateCancer #GICancer #BreastCancer #OvarianCancer #CervicalCancer
NSCLC update supported by an Independent Educational Grant from Bayer.Other updates supported by COR2ED
#MedEd @lizzysmyth.bsky.social
Expert insights on the latest data: cor2ed.com/n-connect/pr...
#NSCLC #ProstateCancer #GICancer #BreastCancer #OvarianCancer #CervicalCancer
NSCLC update supported by an Independent Educational Grant from Bayer.Other updates supported by COR2ED
#MedEd @lizzysmyth.bsky.social
Highlights from ASCO 2025 | COR2ED
cor2ed.com
June 12, 2025 at 12:25 PM
📣Update from #ASCO25
Expert insights on the latest data: cor2ed.com/n-connect/pr...
#NSCLC #ProstateCancer #GICancer #BreastCancer #OvarianCancer #CervicalCancer
NSCLC update supported by an Independent Educational Grant from Bayer.Other updates supported by COR2ED
#MedEd @lizzysmyth.bsky.social
Expert insights on the latest data: cor2ed.com/n-connect/pr...
#NSCLC #ProstateCancer #GICancer #BreastCancer #OvarianCancer #CervicalCancer
NSCLC update supported by an Independent Educational Grant from Bayer.Other updates supported by COR2ED
#MedEd @lizzysmyth.bsky.social
📹 Watch the video: cor2ed.com/n-connect/pr...
Video: Recognising #hypophosphatasia (HPP)🔍
- Key manifestations
- Common misdiagnoses
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #EULAR2025
Video: Recognising #hypophosphatasia (HPP)🔍
- Key manifestations
- Common misdiagnoses
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #EULAR2025
Rethinking hypophosphatasia (HPP) diagnosis and disease burden | COR2ED
cor2ed.com
June 12, 2025 at 8:11 AM
📹 Watch the video: cor2ed.com/n-connect/pr...
Video: Recognising #hypophosphatasia (HPP)🔍
- Key manifestations
- Common misdiagnoses
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #EULAR2025
Video: Recognising #hypophosphatasia (HPP)🔍
- Key manifestations
- Common misdiagnoses
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #EULAR2025
📣Highlights from #ESMO Breast Cancer 2025 Satellite Symposium
Experts discuss treatment strategies/sequencing after ET+CDK4/6i for ER+/HER2- metastatic #breastcancer
cor2ed.com/n-connect/pr...
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
Experts discuss treatment strategies/sequencing after ET+CDK4/6i for ER+/HER2- metastatic #breastcancer
cor2ed.com/n-connect/pr...
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium | COR2ED
In this conference update video, Profs. Wolfgang Janni, Sherko Kümmel and Michail Ignatiadis provide key insights from the highly anticipated ESMO Breast
cor2ed.com
May 26, 2025 at 9:45 AM
📣Highlights from #ESMO Breast Cancer 2025 Satellite Symposium
Experts discuss treatment strategies/sequencing after ET+CDK4/6i for ER+/HER2- metastatic #breastcancer
cor2ed.com/n-connect/pr...
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
Experts discuss treatment strategies/sequencing after ET+CDK4/6i for ER+/HER2- metastatic #breastcancer
cor2ed.com/n-connect/pr...
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
Chemotherapy strategies in mPDAC
➡️How to choose & optimise the different chemotherapeutic options at 1st & 2nd line
w/ Profs. Efrat Dotan & Shubham Pant
📹 Watch the video/listen on Spotify/Apple cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
➡️How to choose & optimise the different chemotherapeutic options at 1st & 2nd line
w/ Profs. Efrat Dotan & Shubham Pant
📹 Watch the video/listen on Spotify/Apple cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) | COR2ED
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive, with a poor prognosis. It is often diagnosed late, and by this time,
cor2ed.com
May 26, 2025 at 9:41 AM
Chemotherapy strategies in mPDAC
➡️How to choose & optimise the different chemotherapeutic options at 1st & 2nd line
w/ Profs. Efrat Dotan & Shubham Pant
📹 Watch the video/listen on Spotify/Apple cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
➡️How to choose & optimise the different chemotherapeutic options at 1st & 2nd line
w/ Profs. Efrat Dotan & Shubham Pant
📹 Watch the video/listen on Spotify/Apple cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
New 2-part animated video series! 🎬
Ep.1 ➡️ 1st line chemotherapy options, key trial data & considering targeted therapy
Ep.2 ➡️ 2nd line chemotherapy options & how earlier treatments impact sequencing
cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
Ep.1 ➡️ 1st line chemotherapy options, key trial data & considering targeted therapy
Ep.2 ➡️ 2nd line chemotherapy options & how earlier treatments impact sequencing
cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
Chemotherapy strategies for metastatic pancreatic ductal adenocarcinoma | COR2ED
In this 2-part video animated series, medical oncologists Prof Eileen O’Reilly and Prof Efrat Dotan provide an overview of the different treatment options
cor2ed.com
May 20, 2025 at 7:49 PM
New 2-part animated video series! 🎬
Ep.1 ➡️ 1st line chemotherapy options, key trial data & considering targeted therapy
Ep.2 ➡️ 2nd line chemotherapy options & how earlier treatments impact sequencing
cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
Ep.1 ➡️ 1st line chemotherapy options, key trial data & considering targeted therapy
Ep.2 ➡️ 2nd line chemotherapy options & how earlier treatments impact sequencing
cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd